Market Cap
$1.7B
SNDX
Syndax Pharmaceuticals Inc
$17.60 ▼ -3.40%
Prev close $18.22Market cap$1.7B
ConsensusStrong Buy
12-mo target$37.55 (+113.3%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)30 New Institutional Positions18 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SNDX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$1.4B
Inst. Activity
30 buys / 18 sells
Insider Activity
$0.00 buy / $2.7M sell
Insider Net $
-$2.7M
SEC Reports
6
Press Releases
3
Price chart 30d -14.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Jul 14, 2026 SEC Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stag
Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for
8-K — Impact 7/10
Jul 8, 2026 Insider
Metzger Michael A sold 32,375 shares
Chief Executive Officer @ $24.24 ($784.8K)
Jul 8, 2026 Insider
Jul 1, 2026 Press Metzger Michael A acquired via exercise 32,375 shares
Chief Executive Officer @ $6.38 ($206.6K)
Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year gra
Impact 2/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
5,658,424 shares ($123.7M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — DOUBLED
2,053,960 shares ($44.9M)
Jun 12, 2026 Insider
Botwood Nicholas A.J. acquired via exercise 31,235 shares
Head of R&D, CMO @ $13.82 ($431.7K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 21, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 11, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Aug 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jun 12, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 13, 2026 | UBS | MAINTAIN | Buy | 55% |
| May 1, 2026 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 10 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 8 | 10 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% |
Price targets
Where 11 covering analysts think SNDX trades over the next 12 months.
$37.55 +113.3% upside Strong Buy
Current$17.60 Low$26.00 Median$37.00 High$57.00 11 analysts
$26.00$57.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 5 neutral · avg impact 4.5/10.Plus 3 press releases.
BULLISH8-K7/10
Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric
Jul 14, 2026
NEUTRAL8-K5/10
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior No
Jun 10, 2026
NEUTRALDEFA14A4/10
Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vo
Jun 4, 2026
NEUTRAL8-K5/10
Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate princi
Jun 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative c
Sep 30, 2026
short_volume
Short Volume: SNDX — 58.9% short (0.3M / 0.6M)
Short: 337,202 | Exempt: 0 | TRF Vol: 572,066 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: SNDX — 56.4% short (0.3M / 0.5M)
Short: 283,166 | Exempt: 0 | TRF Vol: 501,973 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: SNDX — 62.5% short (0.5M / 0.9M)
Short: 541,292 | Exempt: 0 | TRF Vol: 865,718 | Short Ratio: 62.5% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: SNDX — 62.8% short (0.6M / 1.0M)
Short: 612,259 | Exempt: 0 | TRF Vol: 974,497 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.48 | $-0.58–$-0.31 | 32.1% | -1.1% | 3↑ 6↓ | $0.1B | 10 |
| Next Q | $-0.44 | $-0.60–$-0.27 | 44.1% | -2.3% | 4↑ 5↓ | $0.1B | 10 |
| Current FY | $-1.95 | $-2.25–$-1.65 | 40.7% | -0.8% | 2↑ 7↓ | $0.3B | 10 |
| Next FY | $-0.85 | $-1.96–$0.10 | 56.2% | -4.7% | 2↑ 8↓ | $0.5B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.475 | — |
| 7d ago | $-0.470 | -0.005 |
| 30d ago | $-0.470 | -0.005 |
| 60d ago | $-0.363 | -0.112 |
| 90d ago | $-0.396 | -0.080 |
Institutional ownership
Which big funds own SNDX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.4B total value (65,233,105 shares) as of 2026-Q2. Top holders: BlackRock,, GOLDMAN, STATE. Net buying activity: 30 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | $197.2M | 13.8% | — |
| GOLDMAN SACHS GROUP INC | 5,861,265 | $128.1M | 9.0% | — |
| STATE STREET CORP | 5,658,424 | $123.7M | 8.7% | ADD +27.7% |
| BANK OF AMERICA CORP /DE/ | 4,045,094 | $88.4M | 6.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,927,892 | $85.9M | 6.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 2,584,136 | $56.5M | 4.0% | — |
| Hood River Capital Management LLC | 2,564,279 | $56.1M | 3.9% | — |
| FRANKLIN RESOURCES INC | 2,286,499 | $50.0M | 3.5% | — |
| MILLENNIUM MANAGEMENT LLC | 2,053,960 | $44.9M | 3.1% | DOUBLED +929.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,921,796 | $42.0M | 2.9% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 4,430,076 | 5,658,424 | +27.7% | $123.7M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 199,524 | 2,053,960 | +929.4% | $44.9M |
| UBS Group AG | ADD | 1,153,662 | 1,893,750 | +64.2% | $41.4M |
| Candriam S.C.A. | ADD | 925,332 | 1,696,040 | +83.3% | $37.0M |
| LOOMIS SAYLES & CO L P | NEW | — | 923,624 | — | $20.2M |
| MORGAN STANLEY | TRIM | 893,933 | 588,979 | -34.1% | $12.9M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 249,407 | 546,517 | +119.1% | $11.9M |
| Qube Research & Technologies Ltd | DOUBLED | 36,047 | 477,182 | +1223.8% | $10.4M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 196,621 | 454,101 | +131.0% | $9.9M |
| Aberdeen Group plc | ADD | 286,969 | 372,766 | +29.9% | $8.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 28 transactions. Net -$2.7M — $0.00 bought, $2.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 32,375 | $24.24 | $784.8K |
| Jul 8, 2026 | Metzger Michael A | Chief Executive Officer | EXERCISE | 32,375 | $6.38 | $206.6K |
| Jun 12, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | EXERCISE | 31,235 | $13.82 | $431.7K |
| Jun 12, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | SELL | 31,235 | $18.14 | $566.6K |
| Jun 11, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | EXERCISE | 22,515 | $13.82 | $311.2K |
| Jun 11, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | SELL | 34,280 | $18.00 | $617.0K |
| Jun 1, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 6,847 | $18.99 | $130.0K |
| Jun 1, 2026 | Goldan Keith A. | Chief Financial Officer | SELL | 1,177 | $18.99 | $22.4K |
| Feb 9, 2026 | Metzger Michael A | Chief Executive Officer | SELL | 17,159 | $21.03 | $360.8K |
| Feb 9, 2026 | Goldan Keith A. | Chief Financial Officer | SELL | 3,410 | $21.03 | $71.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SNDX.
Shares short
20,660,449
Settlement Sep 15, 2026
Change vs prior
-4.7%
Semi-monthly cycle
Days to cover
14.7
At avg daily volume
Of shares outstanding
≈23.1%
Estimate — not % of float
All SNDX filing & press-release reports (9)
- 8-K reportJul 14, 2026
- PRESS-RELEASE reportJul 1, 2026
- PRESS-RELEASE reportJun 11, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportJun 4, 2026
- DEFA14A reportJun 4, 2026
- 8-K reportJun 4, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 24, 2026